IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0032530.html
   My bibliography  Save this article

Economic Evaluation of First-Line Treatments for Metastatic Renal Cell Carcinoma: A Cost-Effectiveness Analysis in A Health Resource–Limited Setting

Author

Listed:
  • Bin Wu
  • Baijun Dong
  • Yuejuan Xu
  • Qiang Zhang
  • Jinfang Shen
  • Huafeng Chen
  • Wei Xue

Abstract

Background: To estimate, from the perspective of the Chinese healthcare system, the economic outcomes of five different first-line strategies among patients with metastatic renal cell carcinoma (mRCC). Methods and Findings: A decision-analytic model was developed to simulate the lifetime disease course associated with renal cell carcinoma. The health and economic outcomes of five first-line strategies (interferon-alfa, interleukin-2, interleukin-2 plus interferon-alfa, sunitinib and bevacizumab plus interferon-alfa) were estimated and assessed by indirect comparison. The clinical and utility data were taken from published studies. The cost data were estimated from local charge data and current Chinese practices. Sensitivity analyses were used to explore the impact of uncertainty regarding the results. The impact of the sunitinib patient assistant program (SPAP) was evaluated via scenario analysis. The base-case analysis showed that the sunitinib strategy yielded the maximum health benefits: 2.71 life years and 1.40 quality-adjusted life-years (QALY). The marginal cost-effectiveness (cost per additional QALY) gained via the sunitinib strategy compared with the conventional strategy was $220,384 (without SPAP, interleukin-2 plus interferon-alfa and bevacizumab plus interferon-alfa were dominated) and $16,993 (with SPAP, interferon-alfa, interleukin-2 plus interferon-alfa and bevacizumab plus interferon-alfa were dominated). In general, the results were sensitive to the hazard ratio of progression-free survival. The probabilistic sensitivity analysis demonstrated that the sunitinib strategy with SPAP was the most cost-effective approach when the willingness-to-pay threshold was over $16,000. Conclusions: Our analysis suggests that traditional cytokine therapy is the cost-effective option in the Chinese healthcare setting. In some relatively developed regions, sunitinib with SPAP may be a favorable cost-effective alternative for mRCC.

Suggested Citation

  • Bin Wu & Baijun Dong & Yuejuan Xu & Qiang Zhang & Jinfang Shen & Huafeng Chen & Wei Xue, 2012. "Economic Evaluation of First-Line Treatments for Metastatic Renal Cell Carcinoma: A Cost-Effectiveness Analysis in A Health Resource–Limited Setting," PLOS ONE, Public Library of Science, vol. 7(3), pages 1-13, March.
    • Handle: RePEc:plo:pone00:0032530
    DOI: 10.1371/journal.pone.0032530
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0032530
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0032530&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0032530?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Corrado Barbui & Tarun Dua & Mark van Ommeren & M Taghi Yasamy & Alexandra Fleischmann & Nicolas Clark & Graham Thornicroft & Suzanne Hill & Shekhar Saxena, 2010. "Challenges in Developing Evidence-Based Recommendations Using the GRADE Approach: The Case of Mental, Neurological, and Substance Use Disorders," PLOS Medicine, Public Library of Science, vol. 7(8), pages 1-8, August.
    2. Christopher J.L. Murray & David B. Evans & Arnab Acharya & Rob M.P.M. Baltussen, 2000. "Development of WHO guidelines on generalized cost‐effectiveness analysis," Health Economics, John Wiley & Sons, Ltd., vol. 9(3), pages 235-251, April.
    3. Adam Wagstaff & Winnie Yip & Magnus Lindelow & William C. Hsiao, 2009. "China's health system and its reform: a review of recent studies," Health Economics, John Wiley & Sons, Ltd., vol. 18(S2), pages 7-23, July.
    4. Jens Hougaard & Lars Østerdal & Yi Yu, 2011. "The Chinese healthcare system," Applied Health Economics and Health Policy, Springer, vol. 9(1), pages 1-13, January.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Chongqing Tan & Liubao Peng & Xiaohui Zeng & Jianhe Li & Xiaomin Wan & Gannong Chen & Lidan Yi & Xia Luo & Ziying Zhao, 2013. "Economic Evaluation of First-Line Adjuvant Chemotherapies for Resectable Gastric Cancer Patients in China," PLOS ONE, Public Library of Science, vol. 8(12), pages 1-1, December.
    2. Xiaohui Zeng & Jonathan Karnon & Siying Wang & Bin Wu & Xiaomin Wan & Liubao Peng, 2012. "The Cost of Treating Advanced Non-Small Cell Lung Cancer: Estimates from the Chinese Experience," PLOS ONE, Public Library of Science, vol. 7(10), pages 1-7, October.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Baeten, Steef & Van Ourti, Tom & van Doorslaer, Eddy, 2013. "Rising inequalities in income and health in China: Who is left behind?," Journal of Health Economics, Elsevier, vol. 32(6), pages 1214-1229.
    2. Pan, Jay & Qin, Xuezheng & Li, Qian & Messina, Joseph P. & Delamater, Paul L., 2015. "Does hospital competition improve health care delivery in China?," China Economic Review, Elsevier, vol. 33(C), pages 179-199.
    3. Michaël Schwarzinger & Jean‐Louis Lanoë & Erik Nord & Isabelle Durand‐Zaleski, 2004. "Lack of multiplicative transitivity in person trade‐off responses," Health Economics, John Wiley & Sons, Ltd., vol. 13(2), pages 171-181, February.
    4. Das Gupta, Monica & Ebenstein, Avraham & Sharygin, Ethan Jennings, 2010. "China's marriage market and upcoming challenges for elderly men," Policy Research Working Paper Series 5351, The World Bank.
    5. Zhiyuan Hou & Ellen Van de Poel & Eddy Van Doorslaer & Baorong Yu & Qingyue Meng, 2014. "Effects Of Ncms On Access To Care And Financial Protection In China," Health Economics, John Wiley & Sons, Ltd., vol. 23(8), pages 917-934, August.
    6. Siying Wang & Liubao Peng & Jianhe Li & Xiaohui Zeng & Lihui Ouyang & Chongqing Tan & Qiong Lu, 2013. "A Trial-Based Cost-Effectiveness Analysis of Erlotinib Alone versus Platinum-Based Doublet Chemotherapy as First-Line Therapy for Eastern Asian Nonsquamous Non–Small-Cell Lung Cancer," PLOS ONE, Public Library of Science, vol. 8(3), pages 1-9, March.
    7. Jay Pan & Peng Wang & Xuezheng Qin & Shufang Zhang, 2013. "Disparity and Convergence: Chinese Provincial Government Health Expenditures," PLOS ONE, Public Library of Science, vol. 8(8), pages 1-6, August.
    8. Jens Hougaard & Lars Østerdal & Yi Yu, 2011. "The Chinese healthcare system," Applied Health Economics and Health Policy, Springer, vol. 9(1), pages 1-13, January.
    9. repec:ran:wpaper:774 is not listed on IDEAS
    10. Quartey, Jonathan D. & Nyarko, Lydia Gyamea, 2022. "Economic Sustainability of Mobile Money Payments in Ghana: Does a Tax on Transactions Matter?," African Journal of Economic Review, African Journal of Economic Review, vol. 10(5), December.
    11. Zhang, Anwen & Nikoloski, Zlatko & Mossialos, Elias, 2017. "Does health insurance reduce out-of-pocket expenditure? Heterogeneity among China's middle-aged and elderly," Social Science & Medicine, Elsevier, vol. 190(C), pages 11-19.
    12. Jing You, 2014. "Dietary change, nutrient transition and food security in fast-growing China," Chapters, in: Raghbendra Jha & Raghav Gaiha & Anil B. Deolalikar (ed.), Handbook on Food, chapter 9, pages 204-245, Edward Elgar Publishing.
    13. Bhattacharyya, Onil & Delu, Yin & Wong, Sabrina T. & Bowen, Chen, 2011. "Evolution of primary care in China 1997–2009," Health Policy, Elsevier, vol. 100(2), pages 174-180.
    14. Strauss, John & Lei, Xiaoyan & Park, Albert & Shen, Yan & Smith, James P. & Yang, Zhe & Zhao, Yaohui, 2010. "Health Outcomes and Socio-Economic Status among the Elderly in China: Evidence from the CHARLS Pilot," IZA Discussion Papers 5152, Institute of Labor Economics (IZA).
    15. Currie, Janet & Lin, Wanchuan & Meng, Juanjuan, 2014. "Addressing antibiotic abuse in China: An experimental audit study," Journal of Development Economics, Elsevier, vol. 110(C), pages 39-51.
    16. Mingsheng Chen & Guixia Fang & Lidan Wang & Zhonghua Wang & Yuxin Zhao & Lei Si, 2015. "Who Benefits from Government Healthcare Subsidies? An Assessment of the Equity of Healthcare Benefits Distribution in China," PLOS ONE, Public Library of Science, vol. 10(3), pages 1-15, March.
    17. Lai, Taavi & Habicht, Jarno & Reinap, Marge & Chisholm, Dan & Baltussen, Rob, 2007. "Costs, health effects and cost-effectiveness of alcohol and tobacco control strategies in Estonia," Health Policy, Elsevier, vol. 84(1), pages 75-88, November.
    18. Mingsheng Chen & Yuxin Zhao & Lei Si, 2014. "Who Pays for Health Care in China? The Case of Heilongjiang Province," PLOS ONE, Public Library of Science, vol. 9(10), pages 1-11, October.
    19. Changjian Pan & Qiuyan Fan & Jing Yang & Dasong Deng, 2019. "Health Inequality Among the Elderly in Rural China and Influencing Factors: Evidence from the Chinese Longitudinal Healthy Longevity Survey," IJERPH, MDPI, vol. 16(20), pages 1-16, October.
    20. Feng Huang & Li Gan`, 2017. "The Impacts of China's Urban Employee Basic Medical Insurance on Healthcare Expenditures and Health Outcomes," Health Economics, John Wiley & Sons, Ltd., vol. 26(2), pages 149-163, February.
    21. Bloom, Gerald, 2011. "Building institutions for an effective health system: Lessons from China's experience with rural health reform," Social Science & Medicine, Elsevier, vol. 72(8), pages 1302-1309, April.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0032530. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.